Amgen/Allergan's rituximab biosimilar could be $4bn blockbus...

Ten drugs filed with regulators have potential to become billion-sellers by 2025 according to new research, with a near-copy of Roche’s rituximab from Amgen and Allergan showing the mo

NICE rejects NHS funding Sanofi/Regeneron's Dupixent in asth...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

NICE chair nominee Nebhrajani to face MP scrutiny next week

Girl loses High Court battle over NICE review of BioMarin’s ...

FDA starts review of Pfizer, Lilly’s non-opioid painkiller

Boehringer bags CHMP backing for Ofev in rare lung disease